We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ILUMYA™

News List

Sun Pharma receives Japan MHLW approval of ILUMYATM for the treatment of Plaque Psoriasis expresspharma
June 30, 2020
ILUMYA is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European Commission approved it in September 2018.
Sun Pharma Announces Data Showing Potential of ILUMYA™ to Improve Psoriatic Arthritis Symptoms americanpharmaceuticalreview
June 20, 2019
Sun Pharmaceutical announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYA™ (tildrakizumab-asmn) in patients with active psoriatic arthritis. The interim analysis revealed that over 71 percent of patients treated with ...